Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03439657 · ClinicalTrials.gov registry record · Phase 3
Immunogenicity and Safety Study of GSK Biologicals' Herpes Zoster Vaccine GSK1437173A When Co-administered With Prevenar13 in Adults Aged 50 Years and Older
A Phase 3 study of Herpes Zoster, sponsored by GlaxoSmithKline.
- Completed
- Registry status
- Phase 3
- Development phase
- 913
- Enrollment target
- 13
- Study locations
NCT03439657: Completed Phase 3 study of Herpes Zoster, sponsored by GlaxoSmithKline.
NCT03439657 is a Phase 3 study of Herpes Zoster that has completed, run by GlaxoSmithKline. The registered enrollment target is 913 participants, below the 2,116-participant average among 16 other Herpes Zoster trials with a reported enrollment target (57% lower). The trial reports 13 study locations across 10 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03439657, a Phase 3 study of Herpes Zoster, has completed, sponsored by GlaxoSmithKline.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 913 participants
- Enrollment target
- 13
- Study locations
Study Summary
The purpose of this study is to assess immunogenicity and safety of GSK Biologicals' HZ vaccine when its first dose is co-administered with a pneumococcal polysaccharide conjugate vaccine (Prevenar13) in adults aged ≥50 YOA, as compared to the control group where the two HZ/su doses are administered subsequent to Prevenar13.
Primary Outcome
Vaccine response rate (VRR) for Varicella Zoster Virus (VZV) anti-glycoprotein E (gE) humoral immunogenicity was determined by Enzyme Limked Immunosorbent Assay (ELISA). The VRR for anti-gE is defined as the percentage of subjects who had at least: a 4-fold increase in the anti-gE antibodies concentration as compared to the pre-vaccination anti-gE antibodies concentration, for subjects who are seropositive at baseline, or, a 4-fold increase in the anti-gE antibodies concentration as compared to
Conditions Studied
Interventions
- BIOLOGICAL HZ/su vaccine GSK1437173A
- BIOLOGICAL Prevenar13
Study Locations (13)
Other
- GSK Investigational Site - Rakvere
- GSK Investigational Site - Tallinn
- GSK Investigational Site - Tartu
North Rhine-Westphalia
- GSK Investigational Site - Essen
- GSK Investigational Site - Goch
Massachusetts
- GSK Investigational Site - Marlborough
North Carolina
- GSK Investigational Site - Salisbury
South Carolina
- GSK Investigational Site - Spartanburg
Nova Scotia
- GSK Investigational Site - Truro
Quebec
- GSK Investigational Site - Sherbrooke
Baden-Wurttemberg
- GSK Investigational Site - Weinheim
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 913 participants |
| Start Date | 2018-04-12 |
| Est. Completion | 2020-03-03 |
| Phase | Phase 3 |
What the finished NCT03439657 record still lists
NCT03439657 is an interventional study that assigns participants to a tested intervention. The registered 913 participants enrollment target is mid-sized for trials with a published cap, below the 2,116-participant average among 16 other Herpes Zoster trials with a reported enrollment target (57% lower).
The record links to 1 condition, with Herpes Zoster appearing as the primary indexed condition, and to 2 interventions - of which HZ/su vaccine GSK1437173A is the first listed.
NCT03439657 lists 13 locations in 10 states (Other, North Rhine-Westphalia, Massachusetts).
Frequently Asked Questions
What is clinical trial NCT03439657 about?
NCT03439657 is a clinical study titled "Immunogenicity and Safety Study of GSK Biologicals' Herpes Zoster Vaccine GSK1437173A When Co-administered With Prevenar13 in Adults Aged 50 Years and Older". The purpose of this study is to assess immunogenicity and safety of GSK Biologicals' HZ vaccine when its first dose is co-administered with a pneumococcal polysaccharide conjugate vaccine (Prevenar13) in adults aged ≥50 YOA, as compared to the control group where the two HZ/su doses are administered...
What is the current status of trial NCT03439657?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 913 participants. The study started on 2018-04-12. Estimated completion is 2020-03-03.
What conditions does trial NCT03439657 study?
This clinical trial studies the following conditions: Herpes Zoster.
What interventions are being tested in trial NCT03439657?
The interventions under investigation include: HZ/su vaccine GSK1437173A (BIOLOGICAL), Prevenar13 (BIOLOGICAL).
Who is sponsoring clinical trial NCT03439657?
This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03439657 being conducted?
This trial has 13 study locations across Massachusetts, North Carolina, South Carolina, Nova Scotia, Quebec. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Herpes Zoster
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03439657's enrollment target sits among peer trials
913 6th of 16 higher than 11 of 16 other Herpes Zoster trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Herpes Zoster trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study on the Long-term Efficacy, Safety and Persistence of Immune Response of a Vaccine Against Herpes Zoster in Older Adults
ACTIVE NOT RECRUITING · Phase 3
-
Study to Evaluate Immunogenicity and Safety Study of GSK Biologicals' Herpes Zoster (HZ) Vaccine GSK1437173A When Co-administered With Pneumovax 23™ in Adults Aged 50 Years and Older
COMPLETED · Phase 3
-
Cross-vaccination Study of GSK Biologicals' Herpes Zoster Subunit (HZ/su) Vaccine (GSK 1437173A) in Subjects Who Previously Received Placebo in ZOSTER-006 (NCT01165177) and ZOSTER-022 (NCT01165229) Studies.
COMPLETED · Phase 3
-
Study to Evaluate Efficacy, Safety and Immunogenicity of GlaxoSmithKline (GSK) Biologicals' Herpes Zoster (HZ) Vaccine GSK1437173A in Adults Aged 70 Years and Older
COMPLETED · Phase 3
-
Safety and Immunogenicity of Recombinant Varicella Zoster Virus Vaccine in People With HIV Who Have a CD4 Count Less Than 300 or Greater Than or Equal to 300 and a Healthy Control Population
RECRUITING · Phase 1
-
Safety of Herpes Zoster Subunit (HZ/su) Vaccine During Pregnancy in Adult Women With Immunocompromised Conditions
ACTIVE NOT RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06131840 · 914 participants · Phase 1
A Study of SGN-CEACAM5C in Adults With Advanced Solid Tumors
- NCT06216548 · 909 participants · NA
E-PRIME For Children With Medical Complexity
- NCT05739955 · 918 participants · NA
Impact of Enhanced Daily Disinfection on Environmental Contamination in Hospital Rooms
- NCT05658497 · 908 participants
Pregnancy Exposure Registry for Vumerity (Diroximel Fumarate)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI